Article
Lilly's Glyxambi, First-in-Class Combination Pill, Approved for T2DM
The dual inhibitor tablet, a combination of an SGLT-2 inhibitor and a DPP-4 inhibitor, is expected to stimulate the pancreas to produce more insulin and stimulate the liver to produce less glucose, and also prevent glucose reabsorption.
The FDA has approved Glyxambi® (empagliflozin/linagliptin) tablets, from Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (T2D) when both empagliflozin and linagliptin are appropriate treatments.
Glyxambi is not recommended in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. Glyxambi has not been studied in patients with a history of pancreatitis, and it is unknown if using Glyxambi increases the risk of developing pancreatitis in these patients.
Link to the complete press release by Eli Lilly: http://bit.ly/1wXXreO
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
